Allergan announces FDA approval nebivolol and valsartan

FDA has approved nebivolol and valsartan (Byvalson—Allergan) 5 mg/80 mg tablets for the treatment of hypertension. The drug is the first and only fixed-dose combination of a beta blocker and angiotensin II receptor blocker available in the United States.

FDA has approved nebivolol and valsartan (Byvalson—Allergan) 5 mg/80 mg tablets for the treatment of hypertension. The drug is the first and only fixed-dose combination of a beta blocker and angiotensin II receptor blocker available in the United States. "The majority of patients with hypertension require two or more medications to achieve their blood pressure goals," said William B White, MD, professor of Medicine and Chief of the Division of Hypertension and Clinical Pharmacology, Calhoun Cardiology Center at UConn Health. "Nebivolol and valsartan are used widely in the management of hypertension and are effective drugs. The new fixed-dose combination Byvalson, that includes these 2 therapies, offers reduction of blood pressure through multiple mechanisms of action." Allergan expects nebivolol and valsartan to be available later this year.